Phase I clinical trials are an essential step in the development of anticancer drugs. The main
goal of these studies is to establish the recommended dose and/or schedule of new drugs or …

Pemetrexed is a new-generation antifolate, approved for the treatment of mesothelioma and
non–small cell lung cancer, currently being evaluated for the treatment of a variety of other …

Acclaimed by the worldwide medical community as" a staple reference text in the medical
oncologist's library"(JAMA), DeVita, Hellman, and Rosenberg's Cancer: Principles and …

Antifolates are the oldest of the antimetabolite class of anticancer agents and were one of
the first modern anticancer drugs. The first clinically useful antifolate, described in 1947, was …

Pemetrexed disodium (ALIMTA®,“pemetrexed”) is a novel, multi-targeted antifolate that has
demonstrated promising clinical activity in a wide variety of solid tumors, including non-small …

This review will discuss the key preclinical and clinical features of antifolates, from
methotrexate (MTX) to pemetrexed and beyond. Despite 50 years of study, definition of the …

Abstract BACKGROUND:: The US Food and Drug Administration approved pemetrexed in
February 2004 for the treatment of malignant pleural mesothelioma (MPM) in combination …

Purpose: To determine toxicities, maximally tolerated dose (MTD), pharmacokinetic profile,
and potential antitumor activity of MTA, a novel antifolate compound which inhibits the …

The natural product carolacton is a macrolide keto-carboxylic acid produced by the
myxobacterium Sorangium cellulosum, and was originally described as an antibacterial …

For patients with advanced non-small cell lung cancer and a good functional status,
platinum-based first-line chemotherapy improves quality of life, reduces disease-related …